DIURETIC REDUCES OVERALL SEVERITY OF CORE BEHAVIORAL SYMPTOMS OF #AUTISM

4423858-undistinguishable-young-girl-behind-pane-depression

Researchers at the Mediterranean Institute of Neurobiology in Marseille, France, using 60 autistic children between the ages of 3 to 11, randomly assigned either a daily dose of a placebo or of bumetanide, a commonly prescribed diuretic to treat heart, lung and kidney conditions.

Several studies suggest that the autistic condition interferes with a neurotransmitter, GABA, that typically puts a damper on neural activity.  Bumetanide helps reinforce the inhibiting actions of  GABA.

Parents of the children who’d taken bumetanide reported that after 3 months of daily treatment, the children were more “present” and engaged in social interactions than they’d been before taking the diuretic.

Lead researcher, Yehezkel Ben-Ari quantified the parents’ observations on a 60-point scale used to assess behaviors associated with autism, finding that the children had improved 5.6 points, enough to move the group average just under the cutoff for severe autism and into the mild to medium category.

“We have some indications that the symptoms particularly ameliorated with bumetanide are the genuine core symptoms of autism, namely communication and social interactions.”

“It’s enough to make me think about trying it on a few of my autism patients who haven’t responded to other interventions,” says Randi Hagerman, a pediatrician studying neurodevelopmental disorders at the University of California, Davis.  He adds that social interactions tend to be reinforcing, so the brain of an autistic child who’s interacting more is likely to reflect more positive development.

A colleague of his, Elizabeth Berry-Kravis, pediatric neurologist at Rush University in Chicago, believes the new study suggests that drugs that reduce neural excitation by blocking substances from neurotransmitters or enhance inhibition by blocking GABA may be helpful for treating autism.  “There seems to be this imbalance between excitation and inhibition in people with autism.”

Ben-Ari and his team are preparing for a larger, multicenter trial in Europe.

Sources:  SmartPlanet, December 27, 2012    ScienceNOW, December 2012    Study published in Translational Psychiatry December 2012

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s